Stereotaxis to Buy Robocath for up to $45M

Stereotaxis revealed that it has begun a deal to acquire Robocath, a venture-backed innovator of robotic technologies for interventional cardiology and neurointerventions.

The acquisition strengthens Stereotaxis’ position as a leading platform for the full spectrum of endovascular procedures, the company said. It combines complementary technologies to offer next-gen, fully integrated robotic solutions for electrophysiology, interventional cardiology and neurointerventions.

Robocath is headquartered in Rouen, France and has developed an advanced mechanical robotic technology for interventional cardiology and neurointerventions. Its flagship R-One+ system, according to the company, is the only commercially available robotic system currently available for percutaneous coronary interventions in Europe. Fifteen commercial R-One+ systems have been installed globally.

The company is building a next-gen system designed to allow simultaneous manipulation of up to five interventional devices. The initial first-in-human procedures were successfully completed in France.

Merging Stereotaxis’ magnetic navigation tech and Robocath’s mechanical robotic system creates a differentiated fully robotic solution for endovascular surgery. Stereotaxis uses computer-controlled magnetic fields for navigating interventional devices’ distal tips and Robocath’s platform offers multi-device control at the bedside.

Stereotaxis said it plans to accelerate development of Robocath’s next-gen system and chase regulatory submissions in the U.S. and EU within two years. Stereotaxis will enhance Robocath’s system with existing proprietary hardware and software embedded within GenesisX, Synchrony, and SynX, enabling advanced functionality including operating room integration, automation, and remote procedures.

Stereotaxis estimates that Robocath will contribute approximately $2 million in annual revenue during the first year post-acquisition. The transaction consideration includes an upfront payment of $20 million, and additional contingent payments of up to $25 million tied to regulatory and commercial milestones, including FDA clearance of Robocath’s next generation system.

Comments from Stereotaxis and Robocath leadership

“Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures,” said David Fischel, Stereotaxis chairman and CEO. “By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine. This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis.”

“For over fifteen years, we have been committed to pioneering the most sophisticated plug-and-play bionic robotic technology for endovascular procedures,” said Philippe Bencteux, Robocath founder and CEO. “Joining Stereotaxis provides the scale, complementary technologies, and strategic alignment needed to accelerate our development and expand our impact. We believe this combination will unlock significant opportunities in rapidly growing markets, which are becoming increasingly receptive to robotics.”